Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: A retrospective study of physician-patient pairs in Taiwan

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2618-2627

  Hsiao, Fei Yuan ^a   Tsai, Yi Wen ^a,b   Huang, Weng Foung ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

celecoxib; cyclooxygenase 2 (COX 2) inhibitors; physician prescribing practice; rofecoxib; withdrawal

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HOSPITAL PHYSICIAN; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PHYSICIAN ATTITUDE; POPULATION RESEARCH; PRESCRIPTION; PRIMARY MEDICAL CARE; RHEUMATOID ARTHRITIS; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

AGED; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LACTONES; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRESCRIPTIONS; PRODUCT RECALLS AND WITHDRAWALS; PYRAZOLES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES; TAIWAN;

EID: 74549225799     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.022     Document Type: Article

References (26)

1. Fitz Gerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygennase-2. N Engl J Med. 345 (2001) 433-442
2. Barozzi N., and Tett S.E. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?. Pharmacoepidemiol Drug Saf. 16 (2007) 1184-1191
3. Lanas A. Review article: Recommendations for the clinical management of patients taking non-steroidal anti-inflammatory drugs-a gastroenterologist's prospective. Aliment Pharmacol Ther. 1 (2005) 16-19
4. Lanas A., and Ferrandez A. NSAID-induced gastrointestinal damage: Current clinical management and recommendations for prevention. Chin J Dig Dis. 7 (2006) 127-133
5. Dai C., Stafford R.S., and Alexander G.C. National trends in cyclooxygenase-2 inhibitor use since market release: Non-selective diffusion of a selectively cost-effective innovation. Arch Intern Med. 165 (2005) 171-177
6. Shireman T.I., and Rigler S.K. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort. Am J Geriatr Pharmacother 4 (2006) 210-218
7. Moride Y., Ducruet T., Boivin J.F., et al. Prescription channeling of COX-2 inhibitors and traditional nonselective non-steroidal anti-inflammatory drugs: A population-based case-control study. Arthritis Res Ther. 7 (2005) R333-R342
8. Bresalier R.S., Sandler R.S., Quan H., et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published correction appears in N Engl J Med. 2006;355:221]. N Engl J Med. 352 (2005) 1092-1102
9. Eisenberg R.S. Learning the value of drugs-is rofecoxib a regulatory success story?. N Engl J Med. 352 (2005) 1285-1287
10. Shaya F.T., Blume S.W., Blanchette C.M., et al. Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population. Arch Intern Med. 165 (2005) 181-186
11. Kimmel S.E., Berlin J.A., Reilly M., et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 142 (2005) 157-164
12. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 365 (2005) 475-481
13. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44 (2005) 677-680
14. Huang W.F., Hsiao F.Y., Tsai Y.W., et al. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: An observational study. Drug Saf. 29 (2006) 261-272
15. Huang W.F., Hsiao F.Y., Wen Y.W., and Tsai Y.W. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): A population-based analysis in Taiwanese adults. Clin Ther. 28 (2006) 1827-1836
16. US Food and Drug Administration. Public health advisory-FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm Accessed October 1, 2008
17. Thiebaud P., Patel B.V., and Nichol M.B. Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. Value Health. 9 (2006) 361-368
18. Rahme E., Hunsche E., Toubouti Y., and Chabot I. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: What is the potential impact of the withdrawal of rofecoxib?. Arthritis Rheum. 55 (2006) 27-34
19. Arellano F.M., Yood M.U., Wentworth C.E., et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf. 15 (2006) 861-872
20. Schneeweiss S., Glynn R.J., Avorn J., and Solomon D.H. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 58 (2005) 98-102
21. Setakis E., Leufkens H.G., and van Staa T.P. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis Rheum. 59 (2008) 1105-1111
22. Layton D., Souverein P.C., Heerdink E.R., et al. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: A cohort study using pharmacy dispensing data in the Netherlands. Drug Saf. 31 (2008) 143-158
23. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification (2003), WHO, Geneva, Switzerland
24. WHO Collaborating Centre for Drug Statistics Methodology. The ATC/DDD system (2008). http://www.whocc.no/atcddd/ Accessed September 29, 2008
25. Solomon S.D., McMurray J.J., Pfeffer M.A., et al., Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 352 (2005) 1071-1080
26. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med. 351 (2004) 1709-1711